Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Riediger, Anja Lisa ^a,b   Dietz, Steffen ^a,b   Schirmer, Uwe ^a,b   Meister, Michael ^b,c   Heinzmann Groth, Ingrid ^c   Schneider, Marc ^b,c   Muley, Thomas ^b,c   Thomas, Michael ^b,c   Sültmann, Holger ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b German Center for Lung Research (DZL)   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULATING TUMOR DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN P21;

ADENOCARCINOMA; AGED; ALLELE; ANTAGONISTS AND INHIBITORS; BLOOD; DISEASE EXACERBATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; TREATMENT FAILURE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ALLELES; CIRCULATING TUMOR DNA; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84988433774     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep33505     Document Type: Article

References (35)

1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136, E359-E386, doi: 10.1002/ijc.29210 (2015).
2. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J Clin 66, 7-30, doi: 10.3322/caac.21332 (2016).
3. Mitsudomi, T. et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23, 2513-2520, doi: 10.1200/JCO.2005.00.992 (2005).
4. Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361, 947-957, doi: 10.1056/NEJMoa0810699 (2009).
5. Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutationpositive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13, 239-246, doi: 10.1016/S1470-2045(11)70393-X (2012).
6. Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12, 735-742, doi: 10.1016/S1470-2045(11)70184-X (2011).
7. Chan, K. C. et al. Cancer genome scanning in plasma: detection of tumor-Associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 59, 211-224, doi: 10.1373/clinchem.2012.196014 (2013).
8. Dawson, S. J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368, 1199-1209, doi: 10.1056/NEJMoa1213261 (2013).
9. Murtaza, M. et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun 6, 8760, doi: 10.1038/ncomms9760 (2015).
10. Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112, doi: 10.1038/nature12065 (2013).
11. Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20, 548-554, doi: 10.1038/nm.3519 (2014).
12. Diaz, L. A., Jr. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540, doi: 10.1038/nature11219 (2012).
13. Marchetti, A. et al. Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. J Thorac Oncol 10, 1437-1443, doi: 10.1097/JTO.0000000000000643 (2015).
14. Marcq, M., Vallee, A., Bizieux, A. & Denis, M. G. Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-Time monitoring of therapeutic response to tyrosine kinase inhibitors? J Thorac Oncol 9, e49-e50, doi: 10.1097/JTO.0000000000000134 (2014).
15. Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536, doi: 10.1038/nature11156 (2012).
16. Oxnard, G. R. et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative nextgeneration genotyping of cell-free plasma DNA. Clin Cancer Res 20, 1698-1705, doi: 10.1158/1078-0432.CCR-13-2482 (2014).
17. Thress, K. S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med 21, 560-562, doi: 10.1038/nm.3854 (2015).
18. Gao, F. et al. Microdroplet digital PCR: detection and quantitation of biomarkers in archived tissue and serial plasma samples in patients with lung cancer. J Thorac Oncol 10, 212-217, doi: 10.1097/JTO.0000000000000349 (2015).
19. Narayan, A. et al. Ultrasensitive measurement of hotspot mutations in tumor DNA in blood using error-suppressed multiplexed deep sequencing. Cancer Res 72, 3492-3498, doi: 10.1158/0008-5472.CAN-11-4037 (2012).
20. Zheng, D. et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep 6, 20913, doi: 10.1038/srep20913 (2016).
21. Diehl, F. et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA 102, 16368-16373, doi: 10.1073/pnas.0507904102 (2005).
22. Jiang, P. et al. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci USA 112, E1317-E1325, doi: 10.1073/pnas.1500076112 (2015).
23. Mouliere, F. et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One 6, e23418, doi: 10.1371/journal. pone.0023418 (2011).
24. Wang, Z. et al. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. PLoS One 9, e110780, doi: 10.1371/journal.pone.0110780 (2014).
25. Felip, E. et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 14, 3867-3874, doi: 10.1158/1078-0432.CCR-07-5186 (2008).
26. Gong, Y. et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 4, e294, doi: 10.1371/journal.pmed.0040294 (2007).
27. dAvella, D. et al. Radiation-induced blood-brain barrier changes: pathophysiological mechanisms and clinical implications. Acta Neurochir Suppl 71, 282-284 (1998).
28. Qin, D. et al. Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier: clinical results. Int J Radiat Oncol Biol Phys 51, 959-962 (2001).
29. Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 21, 795-801, doi: 10.1038/nm.3870 (2015).
30. Sorensen, B. S. et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer 120, 3896-3901, doi: 10.1002/cncr.28964 (2014).
31. Diehl, F. et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 14, 985-990, doi: 10.1038/nm.1789 (2008).
32. Maheswaran, S. et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359, 366-377, doi: 10.1056/NEJMoa0800668 (2008).
33. Rosell, R. et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-Treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 17, 1160-1168, doi: 10.1158/1078-0432.CCR-10-2158 (2011).
34. Bronkhorst, A. J., Aucamp, J. & Pretorius, P. J. Cell-free DNA: Preanalytical variables. Clin Chim Acta 450, 243-253, doi: 10.1016/j. cca.2015.08.028 (2015).
35. van der Vaart, M. & Pretorius, P. J. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem 43, 26-36, doi: 10.1016/j.clinbiochem.2009.08.027 (2010).